# reload+after+2024-01-23 22:32:33.078977
address1§Cedar Brook Corporate Center
address2§4-B Cedar Brook Drive
city§Cranbury
state§NJ
zip§08512
country§United States
phone§609 495 2200
fax§609 495 2202
website§https://palatin.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
fullTimeEmployees§34
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Carl  Spana Ph.D.', 'age': 61, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1962, 'fiscalYear': 2023, 'totalPay': 979000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stephen T. Wills CPA, MST', 'age': 66, 'title': 'CFO, COO, Executive VP, Treasurer & Secretary', 'yearBorn': 1957, 'fiscalYear': 2023, 'totalPay': 910550, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Burns  McClellan', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stephen A. Slusher Esq.', 'title': 'Chief Legal Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael B. Raizman M.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James E. Hattersley', 'age': 63, 'title': 'Senior Vice President of Business Development', 'yearBorn': 1960, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  Dodd Ph.D.', 'title': 'Senior Vice President of Preclinical Development', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Jordan', 'title': 'Senior Vice President of Program Operations', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.082
priceToSalesTrailing12Months§6.2031226
currency§USD
dateShortInterest§1702598400
forwardEps§-0.66
exchange§ASE
quoteType§EQUITY
shortName§Palatin Technologies, Inc.
longName§Palatin Technologies, Inc.
firstTradeDateEpochUtc§876922200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ef61cf2b-791e-37b7-b04c-9ccb76a1630d
gmtOffSetMilliseconds§-18000000
targetHighPrice§70.0
targetLowPrice§6.0
targetMeanPrice§42.0
targetMedianPrice§50.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§0.505
grossMargins§-2.6042898
ebitdaMargins§0.0
trailingPegRatio§None
